Genes, synecdoche and the possibility of editing ourselves
By Kurt Cobb,
Resilience
| 05. 20. 2018
Margaret Atwood’s 2003 novel Oryx and Crake depicts the evolution and aftermath of a bioengineered global catastrophe. Whether Atwood at the time was privy to insider knowledge that genetic alteration would become easy to do and ubiquitous or whether she just thought it would make a good premise for a novel, I do not know.
What we have now, however, is a world moving ever forward toward what is being called the democratization of genetic engineering or biohacking for short. Anyone with a credit card and a mailing address can now order their own genetic engineering kit. Meanwhile, in major research laboratories around the world visits from awed reporters are bringing the possibility of fabulous advances in medicine to the attention of the public.
Some 6,000 diseases are thought to be linked to our genetic structure. Could these diseases not only be prevented in newly forming humans in utero, but also cured on the fly in fully fledged humans through means that alter their DNA? The preliminary answer is possibly.
Of course, there is concern that gene manipulation...
Related Articles
By Jason Liebowitz, The New Yorker | 03.06.2026
When Talaya Reid was in high school, in a quiet suburb of Philadelphia, she developed fatigue so severe that she spent afternoons napping instead of going out with friends. She was lethargic at school and her grades suffered, but after...
By Émile P. Torres, Truthdig | 02.26.2026
It’s well known that Jeffrey Epstein was a super-wealthy pedophile with an extraordinary network of powerful friends: tech billionaires, politicians and academics. But few people know that he was also a transhumanist — someone who believes that we should...
By Scott Solomon, The MIT Press Reader | 02.12.2026
Chris Mason is a man in a hurry.
“Sometimes walking from the subway to the lab takes too long, so I’ll start running,” he told me over breakfast at a bistro near his home in Brooklyn on a crisp...
By Zachary Brennan, Endpoints News | 02.23.2026
The FDA is spelling out the details of a new pathway to help speed personalized cell and gene therapies to market for rare diseases.
Monday’s long-awaited draft guidance outlines the agency’s “plausible mechanism” framework, a pathway FDA Commissioner Marty Makary...